Crystalline Polymorphs of a Cardiac Myosin Modulator for Stability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac sarcomere-targeting agents for conditions like hypertrophic cardiomyopathy and heart failure with preserved ejection fraction have poor selectivity, leading to adverse effects and limited therapeutic index, necessitating the development of more selective and stable forms of the compound 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde for improved cardiac function.
Innovation Solution
The development of polymorphic forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde, specifically crystalline Forms I, II, and III, with controlled stability and solubility, to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cardiac sarcomere-targeting agents are used, then cardiac contractility is improved, but selectivity is poor leading to adverse effects
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: the core triazaspiro structure provides selective cardiac myosin binding, while specific substituent groups (difluorobenzyl, methylcyclohexyl) fine-tune selectivity and pharmacokinetic properties. This localized functional differentiation enables high cardiac selectivity without affecting smooth muscle myosin, thereby improving therapeutic index while minimizing adverse effects.
2Productivity
If large scale production processes are used, then manufacturing efficiency is improved, but control over polymorph stability becomes difficult
Solution Approach 1:
The patent applies preliminary action by pre-characterizing multiple polymorphic forms (Forms I, II, and III) with their distinct stability profiles, solubility characteristics, and interconversion behaviors before scale-up. This advance understanding enables selection of the most stable polymorph for large-scale production and implementation of appropriate process controls to prevent unwanted polymorphic transitions during manufacturing, storage, and distribution.
3Reliability
If different crystalline forms are developed, then stability and solubility are improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions (solvent type, temperature, pH, additives) to generate and characterize different polymorphic forms. Each form (I, II, III) possesses distinct physical parameters including stability, solubility, and melting point. This structured approach to parameter optimization enables selection of the most suitable polymorph for the intended application while establishing standardized manufacturing protocols to manage complexity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Provided herein are crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde, compositions thereof, methods of preparation thereof, and methods of their uses.